Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
2% CHG · 1 trial · 1 indication
To measure the dosage of the coverage area of a single investigational test article, Medline 2% CHG cloth calculated in grams per square centimeter
| Arm | Type | Description |
|---|---|---|
| Chlorhexidine Gluconate | EXPERIMENTAL | 2% CHG |
| Name | Type | Description |
|---|---|---|
| 2% CHG | DRUG | Chlorhexidine Gluconate |
Inclusion Criteria: Healthy males of at least 18 years of age having skin within 6 inches of the test regions that were free of tattoos, dermatoses, abrasions, cuts, lesions or other skin disorders, with no history of sensitivity to CHG and were able to lie prone for up to 30 minutes.
2% CHG is a small molecule being developed by Medline Inc. for skin coverage in dermatology. It is currently in Phase 2 clinical development as an investigational drug. The drug is a 2% chlorhexidine gluconate formulation intended for topical application to the skin.
2% CHG is being developed by Medline Inc., a company traded under the ticker MDLN. The drug is currently in Phase 2 clinical development for skin coverage in the dermatology therapeutic area. Medline Inc. is the sponsor of the clinical trial evaluating this investigational drug.
2% CHG is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for skin coverage in dermatology, and one Phase 2 clinical trial has been completed.
2% CHG has one completed Phase 2 clinical trial, NCT03326726, titled 'Evaluation 2% Chlorhexidine Gluconate'. The trial enrolled 30 healthy male volunteers aged 18 years and older to evaluate the drug for skin coverage. The study was uncontrolled and not randomized or double-blinded.
2% CHG is a formulation containing 2% chlorhexidine gluconate, which is the active ingredient. The drug is being developed by Medline Inc. for skin coverage. The clinical trial NCT03326726 evaluates this 2% chlorhexidine gluconate formulation in healthy volunteers.